Rebecca Pigula

CIL is a leading provider of growth strategy and commercial due diligence to PE, portfolio companies and corporates more widely. Rebecca has particular expertise in tech-enabled business services and life sciences, where she has supported firms across the value chain maximize their growth potential. Engagements span drug discovery to clinical trials, regulatory affairs, commercialization, and manufacturing. She has vast experience supporting PE and management teams with investment decision making, international expansion, new service and technology development.